vs
Side-by-side financial comparison of HA Sustainable Infrastructure Capital, Inc. (HASI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $114.8M, roughly 1.5× HA Sustainable Infrastructure Capital, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -46.8%, a 48.5% gap on every dollar of revenue. On growth, HA Sustainable Infrastructure Capital, Inc. posted the faster year-over-year revenue change (13.3% vs 5.0%). Over the past eight quarters, HA Sustainable Infrastructure Capital, Inc.'s revenue compounded faster (4.2% CAGR vs -0.2%).
HA Sustainable Infrastructure Capital, Inc. (HASI) is a specialized investment firm focused on sustainable infrastructure assets covering renewable energy, energy efficiency, sustainable real estate and low-carbon utility segments. It primarily operates in North American markets, providing long-term capital to eligible sustainable projects and delivering stable risk-adjusted returns to investors through recurring cash flows from operational underlying assets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HASI vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $114.8M | $177.4M |
| Net Profit | $-53.8M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -57.4% | 3.9% |
| Net Margin | -46.8% | 1.6% |
| Revenue YoY | 13.3% | 5.0% |
| Net Profit YoY | -176.7% | — |
| EPS (diluted) | $-0.38 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $114.8M | $196.9M | ||
| Q3 25 | $103.1M | $179.5M | ||
| Q2 25 | $85.7M | $181.1M | ||
| Q1 25 | $96.9M | $168.9M | ||
| Q4 24 | $101.3M | $187.3M | ||
| Q3 24 | $82.0M | $168.6M | ||
| Q2 24 | $94.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-53.8M | — | ||
| Q3 25 | $83.3M | $5.4M | ||
| Q2 25 | $98.4M | $-4.8M | ||
| Q1 25 | $56.6M | $4.8M | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $-19.6M | $-143.5M | ||
| Q2 24 | $26.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -57.4% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | 84.7% | 1.2% | ||
| Q4 24 | 90.9% | 13.2% | ||
| Q3 24 | -32.1% | -82.8% | ||
| Q2 24 | 39.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -46.8% | — | ||
| Q3 25 | 80.8% | 3.0% | ||
| Q2 25 | 114.9% | -2.7% | ||
| Q1 25 | 58.4% | 2.8% | ||
| Q4 24 | 69.2% | — | ||
| Q3 24 | -23.9% | -85.1% | ||
| Q2 24 | 28.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.38 | $0.05 | ||
| Q3 25 | $0.61 | $0.12 | ||
| Q2 25 | $0.74 | $-0.11 | ||
| Q1 25 | $0.44 | $0.10 | ||
| Q4 24 | $0.58 | $0.38 | ||
| Q3 24 | $-0.17 | $-3.11 | ||
| Q2 24 | $0.23 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $653.9M |
| Total Assets | $8.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $110.2M | $238.4M | ||
| Q3 25 | $301.8M | $246.3M | ||
| Q2 25 | $86.5M | $445.9M | ||
| Q1 25 | $67.4M | $493.6M | ||
| Q4 24 | $129.8M | $484.6M | ||
| Q3 24 | $44.1M | $453.8M | ||
| Q2 24 | $145.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $2.7B | $693.1M | ||
| Q3 25 | $2.7B | $727.2M | ||
| Q2 25 | $2.6B | $757.8M | ||
| Q1 25 | $2.5B | $798.5M | ||
| Q4 24 | $2.4B | $778.3M | ||
| Q3 24 | $2.3B | $749.6M | ||
| Q2 24 | $2.3B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $8.2B | $1.3B | ||
| Q3 25 | $8.2B | $1.3B | ||
| Q2 25 | $7.6B | $1.5B | ||
| Q1 25 | $7.5B | $1.6B | ||
| Q4 24 | $7.1B | $1.6B | ||
| Q3 24 | $6.7B | $1.5B | ||
| Q2 24 | $6.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $167.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.3M | $43.7M | ||
| Q3 25 | $-121.8M | $60.8M | ||
| Q2 25 | $79.6M | $12.0M | ||
| Q1 25 | $-37.1M | $35.5M | ||
| Q4 24 | $5.9M | $33.1M | ||
| Q3 24 | $21.9M | $53.9M | ||
| Q2 24 | $-24.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -1.46× | 11.20× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | -0.66× | 7.37× | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.94× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HASI
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
